Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort study
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70009 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Flavia Hodel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine Unit, Biomedical Data Science Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Pharmacogenomic Variants. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Drug type and dosing recommendation have been designed and optimized based on average response in the general population. Yet, there is significant inter‐individual variability in drug response, which results in treatment inefficacy or adverse drug reactions in a subset of patients. This is partly due to genetic factors that typically affect drug metabolism or clearance. To verify the relevance and applicability of international pharmacogenetic guidelines in the Swiss population, we genotyped 1533 patients from a hospital‐based biobank who received at least 30 different drugs, as documented in their electronic health record. We then assessed the prevalence of clinically actionable variants in 13 high‐risk pharmacogenes. We compared the allele frequencies obtained in the hospital‐based cohort with those of a Swiss population‐based cohort of 4791 individuals. The prevalence of clinically actionable variants was comparable between the two cohorts, with most study participants (97.3%) carrying at least one actionable pharmacogenetic variant. We then assessed the frequency of high‐risk prescriptions due to actionable gene–drug interactions and observed that 31% of patients in the hospital‐based cohort were prescribed at least one drug for which they carried a high‐risk variant, and for which international guidelines recommend a change of drug or dosage. Our analysis confirms the high prevalence of actionable pharmacogenetic variants in the Swiss population. It also shows that a substantial minority of patients are exposed to drugs for which they carry potentially problematic variants. Implementing a genetically informed approach to drug prescribing could have a positive impact on the quality of healthcare delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Precision Medicine Unit, Biomedical Data Science Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Division of Internal Medicine, Department of Medicine, University of Lausanne and University Hospital of Lausanne, Lausanne, Switzerland.
- Division of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Global Health Institute, School of Life Sciences, EPFL, Lausanne, Switzerland.
- Swiss Institute of Bioinformatics, Lausanne, Switzerland.
ORCID-Profile: Flavia Hodel, François Girardin
Zitieren
APA
Hodel, F., De Min, M. B., Thorball, C. W., Redin, C., Vollenweider, P., Girardin, F., & Fellay, J. (2024). Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort study. Clinical and Translational Science. https://doi.org/10.1111/cts.70009
Vancouver
Hodel F, De Min MB, Thorball CW, Redin C, Vollenweider P, Girardin F, et al. Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort study. Clinical and Translational Science. 2024. doi:10.1111/cts.70009
BibTeX
@article{Hodel2024,
author = {Hodel, Flavia and De Min, Maria B and Thorball, Christian Wandall and Redin, Claire and Vollenweider, Peter and Girardin, François and Fellay, Jacques},
title = {Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort study},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70009}
}
EUVIMED